BI 1810631 (C-14) clinical trials

A phase I, open-label trial in two parallel parts to investigate mass balance, metabolism, and basic pharmacokinetics of BI 1810631 (C-14) administered as oral solution (part A) and to investigate absolute bioavailability of BI 1810631 administered as film-coated tablet together with an intravenous microtracer dose of BI 1810631 (C-14) (part B) in healthy male volunteers

This study looks at how a new medicine, BI 1810631, travels through the body and how much reaches the bloodstream. It helps us understand how the body processes the medicine when taken as a liquid or a tablet.